Wall Street Futures Slip as Oracle Earnings Miss Reignites AI Spending Concerns 
US Signals Openness to New Trade Deal as Brazil Shows Willingness, Says USTR Greer 
SoftBank Eyes Switch Inc as It Pushes Deeper Into AI Data Center Expansion 
JD.com Pledges 22 Billion Yuan Housing Support for Couriers as China’s Instant Retail Competition Heats Up 
Gold Prices Hold Firm as Markets Await Fed Rate Cut; Silver Surges to Record High 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
Fed Near Neutral Signals Caution Ahead, Shifting Focus to Fixed Income in 2026 
Wall Street Futures Dip as Broadcom Slides, Tech Weighed Down Despite Dovish Fed Signals 
Nvidia Develops New Location-Verification Technology for AI Chips 
S&P 500 Slides as AI Chip Stocks Tumble, Cooling Tech Rally 
SK Hynix Considers U.S. ADR Listing to Boost Shareholder Value Amid Rising AI Chip Demand 
Global Markets Slide as Tech Stocks Sink, Yields Rise, and AI Concerns Deepen 
Apple App Store Injunction Largely Upheld as Appeals Court Rules on Epic Games Case 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
Asian Currencies Hold Steady as Indian Rupee Slides to Record Low on Fed Outlook 
Merck KGaA has signed partnership deals with BenevolentAI and Exscientia for its AI-driven drug discovery push. The German science and technology company is collaborating with these AI drug discovery firms to strengthen its own capabilities in designing and creating new drugs using artificial intelligence.
As per Fierce BioTech, Merck KGaA is betting on an AI-enabled future for drug discovery the new deals with BenevolentAI and Exscientia are part of its strategy to meet its own goals. Based on the reports, the contracts are worth over $30 million upfront and up to $1 billion in possible milestone arrangements.
In any case, with its collaborations with two leading AI drug discovery groups, Merck just bolstered its chances of yielding successful results for its targeted development and production of new drugs on three leading categories in the medical fields, which are immunology, neuroinflammation, cancer, and neurology
Merck’s global head of R&D also said that the incorporation of science, AI, and data could allow them to find and produce “previously unimaginable medical breakthroughs.” Although the AI-enabled drug discovery method is still in the early stages, the company is positive that it will achieve its goals while also becoming a pioneer in this field.
“With the convergence of science, data, and AI, we're determined to fast-track the development of new and truly innovative candidates, forging a path to previously unimaginable medical breakthroughs,” Merck’s global head of research and development and chief medical officer for the healthcare business unit, Danny Bar-Zohar, said in a press release.
He added, “The partnerships with industry-leading AI technology firms BenevolentAI and Exscientia will complement our internal research capabilities and expertise, aligning with our broader strategy to enhance R&D productivity and the output of our pipeline in a sustainable manner.”
Photo by: Merck Group Media Gallery
